Patents Assigned to KARYOPHARM THERAPEUTICS, INC.
-
Patent number: 11945794Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.Type: GrantFiled: August 23, 2021Date of Patent: April 2, 2024Assignee: Karyopharm Therapeutics Inc.Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
-
Patent number: 11807629Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: July 1, 2021Date of Patent: November 7, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11787771Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.Type: GrantFiled: May 14, 2021Date of Patent: October 17, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Vincent P. Sandanayaka, Sharon Shacham, Dilara McCauley, Sharon Shechter
-
Patent number: 11753401Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: April 5, 2023Date of Patent: September 12, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11746102Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: April 7, 2023Date of Patent: September 5, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11124493Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.Type: GrantFiled: July 23, 2019Date of Patent: September 21, 2021Assignee: Karyopharm Therapeutics Inc.Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
-
Patent number: 11078190Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: November 11, 2019Date of Patent: August 3, 2021Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11034660Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.Type: GrantFiled: November 26, 2019Date of Patent: June 15, 2021Assignee: Karyopharm Therapeutics Inc.Inventors: Vincent P. Sandanayaka, Sharon Shacham, Dilara McCauley, Sharon Shechter
-
Patent number: 11008309Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.Type: GrantFiled: July 10, 2019Date of Patent: May 18, 2021Assignee: Karyopharm Therapeutics Inc.Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
-
Patent number: 10858347Abstract: The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 29, 2016Date of Patent: December 8, 2020Assignee: Karyopharm Therapeutics Inc.Inventor: Erkan Baloglu
-
Patent number: 10544108Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.Type: GrantFiled: November 28, 2018Date of Patent: January 28, 2020Assignee: Karyopharm Therapeutics Inc.Inventors: Vincent P. Sandanayaka, Sharon Shacham, Dilara McCauley, Sharon Shechter
-
Patent number: 10526295Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.Type: GrantFiled: December 30, 2016Date of Patent: January 7, 2020Assignee: Karyopharm Therapeutics Inc.Inventor: Erkan Baloglu
-
Patent number: 10519139Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: August 14, 2015Date of Patent: December 31, 2019Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 10407405Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.Type: GrantFiled: July 17, 2017Date of Patent: September 10, 2019Assignee: Karyopharm Therapeutics Inc.Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
-
Patent number: 10399963Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.Type: GrantFiled: December 4, 2017Date of Patent: September 3, 2019Assignee: Karyopharm Therapeutics Inc.Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
-
Patent number: 10363247Abstract: The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by Structural Formula 1a: (I) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of Structural Formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 18, 2016Date of Patent: July 30, 2019Assignee: Karyopharm Therapeutics Inc.Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis
-
Patent number: 10202366Abstract: The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R1, R2 and n are as defined and described herein, in a method for promoting wound healing in a subject.Type: GrantFiled: March 14, 2014Date of Patent: February 12, 2019Assignee: Karyopharm Therapeutics Inc.Inventors: Tami Rashal, Dilara McCauley, Sharon Shacham, Erkan Baloglu
-
Patent number: 10173987Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.Type: GrantFiled: June 21, 2017Date of Patent: January 8, 2019Assignee: Karyopharm Therapeutics Inc.Inventors: Vincent P. Sandanayaka, Sharon Shacham, Dilara McCauley, Sharon Shechter
-
Patent number: 9994558Abstract: The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).Type: GrantFiled: September 19, 2014Date of Patent: June 12, 2018Assignee: Karyopharm Therapeutics Inc.Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
-
Patent number: 9938258Abstract: The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.Type: GrantFiled: November 27, 2013Date of Patent: April 10, 2018Assignee: Karyopharm Therapeutics Inc.Inventors: Erkan Baloglu, Sharon Shechter, Sharon Shacham, Dilara McCauley, William Senapedis, Gali Golan, Ori Kalid